Research Article
Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters
Table 2
Genotype frequencies of MPO −463G>A, NQO1 609C>T, CYP2E1 −1293G>C/−1053C>T, GSTT1, and GSTM1 polymorphisms using the dominant genetic model in SCA patients treated (SCA-HU+) and untreated (SCA-HU−) with HU.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SCA-HU+: SCA patient treated with HU; SCA-HU−: SCA patient untreated with HU; MPO: myeloperoxidase; CYP2E1: cytochrome P450 2E1; GSTT1/GSTM1: glutathione S-transferase T1/M1; NQO1: NADP(H) quinone oxidoreductase; N: number; corrected Yates, exact Fisher test; OR: odds ratio; 95% CI: 95% confidence interval. |